Results 11 to 20 of about 10,317 (226)
Ocular myasthenia gravis in a setting of thyrotoxicosis
Indian Journal of Endocrinology and Metabolism, 2013 Ocular myasthenia gravis in conjunction with thyroid disorders, although rare, has been reported in the past. However, the similarity in the presentation of both the entities and the tendency of myasthenia gravis to get overlooked easily, even by ...
Sarabjeet Chhabra, B C Pruthvi
doaj +3 more sources
Ocular myasthenia gravis: A review
Indian Journal of Ophthalmology, 2014 Myasthenia gravis (MG) is a disease that affects the neuro-muscular junction resulting in classical symptoms of variable muscle weakness and fatigability. It is called the great masquerader owing to its varied clinical presentations.
Akshay Gopinathan Nair +3 more
doaj +3 more sources
Controversies in Ocular Myasthenia Gravis [PDF]
Frontiers in Neurology, 2020 Myasthenia gravis (MG) with symptoms limited to eye muscles [ocular MG (OMG)] is a rare disease. OMG incidence varies according to ethnicity and age of onset. In recent years, both an increase in incidence rate, particularly in the elderly, and a lower risk for secondary generalization may have contributed to the growing disease prevalence in Western ...
Amelia Evoli +3 more
openaire +3 more sources
Features of depression development in myasthenia gravis.
Medičnì Perspektivi, 2020 The relative risk of developing depression in myasthenia gravis is 2.14 times higher than in the general population. The features of depression in myasthenia patients remain poorly understood and need to be clarified.
O. I. Kalbus +4 more
doaj +1 more source
Neurologijos seminarai, 2022 Myasthenia gravis is a chronic autoimmune neuromuscular disorder typically presenting with variable skeletal muscle fatigue. The most prevalent initial manifestation of myasthenia is ocular myasthenia.
J. Zakaravičiūtė, M. Šerelytė
doaj +3 more sources
Clinical predictors for the prognosis of myasthenia gravis
BMC Neurology, 2017 Background Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified.
Lili Wang, Yun Zhang, Maolin He
doaj +1 more source
Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis : a subgroup analysis of the REGAIN open-label extension study [PDF]
, 2019 The terminal complement inhibitor eculizumab was shown to improve myasthenia gravis-related symptoms in the 26-week, phase 3, randomized, double-blind, placebo-controlled REGAIN study (NCT01997229).
De Bleecker, Jan +12 more
core +1 more source
Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis [PDF]
, 2015 PURPOSE: To calculate the rate and timing of conversion from ocular myasthenia gravis to generalized myasthenia gravis. DESIGN: Retrospective multicenter analysis. SUBJECTS: Patients included in the study were diagnosed with ocular myasthenia gravis
Abusamra, K +4 more
core +1 more source
Ocular myasthenia gravis: Side effect of urografin
Heart India, 2016 Ocular myasthenia gravis is an autoimmune disorder of the neuromuscular junction. Diplopia and ptosis are common symptoms at the onset of ocular myasthenia gravis. It may occur due to the antibodies developed against various drugs.
Nitin Modi +3 more
doaj +1 more source
New acute onset of ocular myasthenia gravis after COVID-19 vaccine: A case report
Journal of Family Medicine and Primary Care, 2023 Reports have shown the association of coronavirus disease 2019 (COVID-19) with several neuromuscular disorders. Myasthenia gravis (MG) is an autoimmune disease in which antibodies bind to acetyl choline receptors in the postsynaptic membrane at the ...
Himani T. Chaturvedi +3 more
doaj +1 more source